July 7, 2020 / 11:27 AM / a month ago

BRIEF-Apellis Completes Enrollment In Two Phase 3 Studies In Patients With Geographic Atrophy

July 7 (Reuters) - Apellis Pharmaceuticals Inc:

* APELLIS COMPLETES ENROLLMENT IN TWO PHASE 3 STUDIES OF THE TARGETED C3 THERAPY, PEGCETACOPLAN, IN PATIENTS WITH GEOGRAPHIC ATROPHY (GA)

* APELLIS PHARMACEUTICALS INC - TOP-LINE RESULTS EXPECTED IN Q3 2021 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below